Psilocybin Nears FDA Approval as First Prescription Psychedelic Therapy

For nearly six decades, psilocybin—the psychoactive compound found in so-called "magic mushrooms"—has languished in Schedule I, deemed to have no accepted medical use and high abuse potential. That classification, which has severely restricted research since 1970, may be overturned within months. Compass Pathways' synthetic psilocybin formulation, COMP360, is now positioned to become the first FDA-approved psychedelic therapy in U.S. history, with approval potentially arriving by late 2026 or early 2027.

The regulatory trajectory shifted dramatically in April 2026. On April 18, President Trump signed an executive order directing federal agencies to accelerate research, review, and approval of psychedelic therapies for serious mental health conditions. Six days later, FDA Commissioner Marty Makary issued National Priority Vouchers to three psychedelic programs—mechanisms that compress the standard 10-to-12-month FDA review timeline to just one to two months.

A New Mechanism for Treatment-Resistant Depression

The target population for COMP360 is substantial: an estimated 2 to 3 million Americans live with treatment-resistant depression, defined as depression that has failed to respond to at least two adequate courses of antidepressant treatment. For these individuals, existing options—primarily esketamine (Spravato) and lithium augmentation—offer limited relief and significant drawbacks.

What distinguishes psilocybin therapy from conventional antidepressants is both its mechanism and its administration. Rather than daily pills, patients receive one to three supervised dosing sessions. Clinical trial data show response occurring as early as the day after treatment, with effects persisting at least six months from just one or two doses. This represents a fundamentally different approach to psychiatric pharmacology—one that prioritizes neuroplasticity and psychological insight over chronic receptor modulation.

"If COMP360 is approved, it would represent the first genuinely new mechanism of action in psychiatric pharmacology since ketamine," notes the clinical research community, "and the first drug in its class to be approved for a psychiatric indication."

Two Consecutive Phase 3 Successes

The path to regulatory submission rests on two pivotal Phase 3 trials. COMP005, completed in June 2025, marked the first positive Phase 3 result for any classic psychedelic in any psychiatric indication in U.S. history. The trial hit its primary endpoint with high statistical significance, demonstrating that COMP360 could produce rapid, substantial reductions in depression symptoms.

COMP006, completed in February 2026, confirmed these findings. The second Phase 3 trial also hit its primary endpoint with high statistical significance, enrolling more than 1,000 participants across both studies. Compass Pathways is now conducting 26-week follow-up assessments, with data expected in early Q3 2026.

Based on this strength of evidence, the FDA granted Compass Pathways permission for rolling New Drug Application submission—allowing the company to submit sections of the application as they are completed rather than waiting for a complete package. The final NDA submission is on track for Q4 2026.

Three Programs in Priority Review

The FDA's April 24 announcement identified three psychedelic therapy programs receiving National Priority Vouchers:

Compass Pathways — COMP360 for treatment-resistant depression is the most advanced, with rolling NDA submission already underway. The company has indicated that any center currently delivering esketamine (Spravato) should be capable of administering COMP360, potentially enabling rapid scaling if approved.

Usona Institute is pursuing psilocybin approval for major depressive disorder—a broader indication than Compass Pathways' treatment-resistant focus—but is less advanced in the NDA process.

Transcend Therapeutics is developing TSND-201, an MDMA-like compound called methylone, for PTSD treatment. This program is subject to acquisition by Otsuka Pharmaceutical Co.

All three programs benefit from the priority voucher mechanism, which could compress FDA review to one to two months once complete applications are submitted.

The Rescheduling Challenge

FDA approval, however, does not guarantee immediate availability. COMP360 remains a Schedule I controlled substance, and commercial distribution requires DEA rescheduling. The April executive order explicitly directed the DEA to "initiate and complete a review of psilocybin's scheduling, so that rescheduling may proceed as quickly as possible" once Phase 3 trials are complete.

The rescheduling process adds an additional timeline variable between FDA approval and clinical availability. Historical precedent suggests this could take months, though the executive order's explicit directive may accelerate the process.

What Patients Should Know

For the 2 to 3 million Americans with treatment-resistant depression, the approaching approval represents genuine hope—but also requires patience and caution.

COMP360 is not yet approved. The FDA has made no final determination, and the drug remains unavailable through legitimate medical channels. Unregulated "retreat" programs, online sources, and unlicensed therapists offering psilocybin therapy operate in legal and clinical gray zones, carrying significant risks.

If approved, COMP360 will not be a take-home prescription. The FDA approval will include a Risk Evaluation and Mitigation Strategy requiring administration only in certified treatment centers by trained clinicians and supervised therapists. Treatment involves preparation sessions before dosing, the dosing session itself (lasting several hours), and integration sessions afterward.

Insurance coverage remains uncertain. Federal approval does not guarantee reimbursement, and the structured, multi-hour nature of treatment complicates coverage decisions by CMS, commercial insurers, and pharmacy benefit managers.

Implications for Addiction Treatment

While COMP360 is being developed for depression, the approval pathway has significant implications for addiction medicine. Psilocybin has shown promise in early trials for alcohol use disorder, tobacco dependence, and opioid use disorder—conditions where existing pharmacotherapies have limited efficacy.

The regulatory infrastructure developed for COMP360—certified treatment centers, trained therapist networks, REMS protocols—could accelerate development of psychedelic therapies for addiction indications. Researchers at Johns Hopkins, NYU, and other institutions have ongoing trials examining psilocybin-assisted therapy for substance use disorders.

The Trump administration's executive order specifically mentioned addiction as a target indication for accelerated psychedelic research, suggesting federal support for expanding beyond depression into substance use disorders.

A Cautious Optimism

The convergence of two positive Phase 3 trials, a presidential executive order, and FDA priority review vouchers places psilocybin closer to medical legitimacy than at any point in the past half-century. For patients who have exhausted conventional antidepressant options, the potential availability of a rapid-acting, durable therapy represents a meaningful advance.

Yet the history of psychiatric drug development counsels restraint. Early enthusiasm for novel mechanisms has often given way to more modest real-world effectiveness. The REMS requirements reflect legitimate safety concerns—psychedelic experiences can be psychologically challenging, and inappropriate administration carries risks of psychological harm.

What is clear is that the regulatory and scientific landscape for psychedelic medicine has shifted fundamentally. Whether COMP360 receives FDA approval in late 2026 or early 2027, the precedent being established opens pathways for a new class of psychiatric treatments that operate through mechanisms fundamentally different from existing medications.

For a field that has seen few genuine innovations in decades, that alone represents a significant development.